[Edaily Reporter Park Jeong-soo] #Prestige Biologics announced on the 10th that it has signed a contract for the contract manufacturing of active pharmaceutical ingredients (APIs) worth 2.66643 billion won. The contract amount represents 21.27% of last year’s revenue, and the contract period runs until March 31 of next year. The identity of the contracting party was not disclosed at the request of the other party to maintain confidentiality. The confidentiality period extends until the end of March next year.
Disclosure Plus
Prestige Biologics Signs 2.7 Billion Won Contract for Contract Manufacturing of Active Pharmaceutical Ingredients
Park Jung-Soo
2026-06-10 15:20:40
Economy
Corporation
IT·Science
Economy
"600 Billion Won from a Single Pixel Game"... The Next Move by a 13-Year-Old Game Developer [VC Cradle]
A single game has generated cumulative sales of 600 billion won. We’re talking about the mobile adventure RPG “Guardian Tales,” which was simultaneously released in approximately 230 countries worldwi…
Corporation
GI Innovation and G2G Bio Jump 20% on Hopes for a Licensing Deal [K-bio pulse]
The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
IT·Science
CEO Cha Sang-hoon, Who Stepped Down from Management: Will He Prove the Value of “SAFA” Through “APB-R3”? [Bio Industry Figures in the Spotlight]
Cha Sang-hoon, CEO of AprilBio Co.,Ltd. (Photo courtesy of AprilBio Co.,Ltd.)
Cha Sang-hoon, CEO of AprilBio Co.,Ltd.(397030), who stepped down from management this year, has seized an opportunity…
